Mycenax Biotech Inc.

Mycenax Biotech and SPERA PHARMA Form Strategic Alliance to Enhance ADC Manufacturing Capabilities

- Mycenax Biotech Inc., a Taiwan-based biologics CDMO, has announced a strategic alliance with Japan's SPERA PHARMA Inc. to enhance antibody-drug conjugate manufacturing services. - The partnership combines Mycenax's expertise in biologics development and manufacturing with SPERA PHARMA's capabilities in pharmaceutical chemistry, manufacturing, and controls processes. - The collaboration aims to optimize workflows and improve efficiency in ADC drug substance and drug product manufacturing to address growing market demand. - Both companies seek to leverage their respective strengths to maintain high-quality standards while streamlining ADC manufacturing workflows for biopharmaceutical clients.